Effects of glucagon-like peptide-1 (GLP-1) mono-agonists on reward processing in animal models: a systematic review.
Yang Jing Zheng, Hezekiah Ching Tin Au, Gia Han Le et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review synthesised 66 preclinical studies of GLP-1 and GLP-1 receptor mono-agonists in animal models, examining food-, drug- and sexual-related reward. Across studies, GLP-1-related interventions generally reduced measures of reward-associated behaviour. Locally administered exenatide was associated with reductions in substance use, food seeking and sexual behaviours, while liraglutide attenuated substance- and food-related rewards (both p < 0.05). Semaglutide reduced substance and sucrose intake, and dulaglutide reduced substance intake (p < 0.001). The authors suggest these findings support further evaluation in psychiatric disorders involving altered hedonic function.
Key findings
- Across 66 preclinical studies, GLP-1 and GLP-1 receptor agonists affected food-, drug- and sexual-related reward measures.
- Locally administered exenatide was associated with reduced substance use, food seeking and sexual behaviours (p < 0.05).
- Liraglutide attenuated substance- and food-related rewards (p < 0.05); semaglutide reduced substance and sucrose intake.
- Dulaglutide was reported to reduce substance intake (p < 0.001).
Why it matters
Reward-related behaviours are relevant to several mental disorders, and this review brings together animal-model evidence that GLP-1 signalling may influence these behaviours. The findings provide a preclinical rationale for investigating GLP-1 receptor agonists in disorders involving altered hedonic function, while not establishing efficacy or safety in people with psychiatric conditions.
What to keep in mind
The evidence is preclinical and comes from animal models; the abstract does not report human studies or establish clinical efficacy.